[211At]Astatine-Based Conditioning with a Humanized CD45 Antibody for Autologous Hematopoietic Stem Cell Gene Therapy
Targeted radiation approach successfully prepares nonhuman primates for gene-edited blood stem cell transplant without harming other organs—a major safety advantage over current conditioning.
A targeted alpha-emitter radioimmunotherapy approach using humanized anti-CD45 antibody labeled with astatine-211 successfully conditions nonhuman primates for autologous gene-edited HSPC transplantation without non-hematopoietic toxicity — a major limitation of current total body irradiation regimens for gene therapy in diseases like sickle cell disease. Sustained 70% gene-editing efficiency in blood at 18+ months and unbiased multilineage contribution confirms durable engraftment with this approach.
What the study was
- Study design
- Nonhuman primate (NHP) preclinical study
- Population
- Nonhuman primates receiving 211At-CD45 RIT conditioning prior to autologous HSPC gene therapy; n=4
- Sample size
- 4
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Blood
Why it surfaced
Novel targeted conditioning strategy for gene therapy with excellent pre-clinical efficacy and safety; Blood journal (top hematology); directly relevant to sickle cell and thalassemia gene therapy programs.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.